|Year : 2019 | Volume
| Issue : 2 | Page : 292-296
Efficacy of a bolus dose of esmolol and bolus dose of lignocaine for attenuating the pressor response to laryngoscopy and endotracheal intubation in general anesthesia: A comparative study
Sridevi Mallanna Mulimani1, Dayanand Gurubasappa Talikoti1, Vinuta Vidyanand Vastrad1, Vijaya Manjunath Sorganvi2
1 Department of Anaesthesia, Shri B M Patil Medical College and Hospital, Bijapur, Karnataka, India
2 Department of Community Medicine, Shri B M Patil Medical College and Hospital, Bijapur, Karnataka, India
|Date of Web Publication||28-May-2019|
Sridevi Mallanna Mulimani
#19 Ghatage Layout, Near Adarsh Nagar Police Station, Solapur Road, Vijayapura, Bijapur, Karnataka
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Context: Laryngoscopy and endotracheal intubation result in an increase in heart rate and blood pressure; they evoke life-threatening complications. The esmolol is short-acting cardioselective beta-blocker and brings advantages to the perioperative management of tachycardia and hypertension. Aims: The aim of this study was to compare the efficacy of a bolus dose of esmolol and bolus dose of lignocaine for attenuation of the pressor response to laryngoscopy and intubation. Settings and Design: Sixty patients of both sex, aged 20–50 years, belonging to the American Society of Anesthesiologists physical Status I and II randomly allocated into two groups (n = 30). Materials and Methods: The study drugs diluted in 10-ml normal saline. Group I received esmolol 1.5 mg/kg and Group II received lignocaine 1.5 mg/kg 2 min before inducing the patients with thiopentone 5 mg/kg and suxamethonium 1.5 mg/kg. The heart rate, systolic blood pressure, and diastolic blood pressure were measured at basal, during intubation, and 1, 2, 3, and 5 min after intubation, and based on these values, the mean arterial pressure (MAP) and rate pressure product (RPP) was calculated. Statistical Analysis Used: The Student's t-test and data were represented by mean standard deviation and graphs. Results: The mean pulse rate, mean of MAP, and mean of RPP at intubation and at 1, 2, 3, and 5 min after intubation in lignocaine group showed a significant rise in these values but in esmolol group it remained nearer to or less than baseline values. Conclusions: Esmolol 1.5 mg/kg is effective in attenuating the pressor response in comparison with lignocaine 1.5 mg/kg during laryngoscopy and intubation.
Keywords: Esmolol, laryngoscopy and endotracheal intubation, lignocaine, pressor response
|How to cite this article:|
Mulimani SM, Talikoti DG, Vastrad VV, Sorganvi VM. Efficacy of a bolus dose of esmolol and bolus dose of lignocaine for attenuating the pressor response to laryngoscopy and endotracheal intubation in general anesthesia: A comparative study. Anesth Essays Res 2019;13:292-6
|How to cite this URL:|
Mulimani SM, Talikoti DG, Vastrad VV, Sorganvi VM. Efficacy of a bolus dose of esmolol and bolus dose of lignocaine for attenuating the pressor response to laryngoscopy and endotracheal intubation in general anesthesia: A comparative study. Anesth Essays Res [serial online] 2019 [cited 2020 Jun 4];13:292-6. Available from: http://www.aeronline.org/text.asp?2019/13/2/292/257589
| Introduction|| |
Laryngoscopy and endotracheal intubation are associated with mechanical stimulation of the respiratory tract, leading to sympathoadrenal stimulation. It manifests as an increase in heart rate, blood pressure, and cardiac complications. Attenuation of these responses by intravenous lignocaine found some studies effective, and in some studies less reliable., Use of esmolol is effective in blunting pressor response and provides hemodynamic stability in risk patients.,,,,
The pressor response during laryngoscopy and intubation was first explained by Reid and Brace in 1940. Yu et al. reported that the tachycardia and hypertension are the main cause of morbidity and mortality in perioperative myocardial infarction. Devereaux et al. showed that the incidence of mortality and morbidity rates are 12%–40% after perioperative myocardial infarction.
Perioperative beta-blockers use in cardiac surgery by Blessberger et al. showed beneficial effects, as they reduce rhythm disturbances, but effect on heart attacks, heart failure, and low blood pressure remains unclear. Esmolol cardioselective β-adrenergic antagonist permits for intraoperative use. It blocks the β-adrenergic receptors and also reduces the force of contraction and heart rate. Varying doses of esmolol 0.5–2 mg/kg have been used in the past. Parvez et al. study supported that attenuation of heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP), and rate pressure product (RPP) using esmolol 1.5 mg/kg. Singh et al. reported that esmolol 2 mg/kg is effective in suppressing the pressor response without any deleterious effects. However, in the literature, no agreement was made in the use of an accurate dose of esmolol for attenuation of hemodynamic response.
Hence, this study was performed to compare the efficacy of an accurate bolus dose of esmolol and bolus dose of lignocaine in attenuating the pressor response to laryngoscopy and endotracheal intubation in general anesthesia with respect to pulse rate (PR), SBP, diastolic blood pressure, MAP, and RPP.
| Materials and Methods|| |
This randomized prospective control study was carried out after obtaining Hospital Ethical Committee clearance (No/58/2015 on 20/11/15) and informed consent from all the patients. Group I was esmolol (n = 30) and Group II was lignocaine (n = 30). Normotensive patients scheduled for surgery under general anesthesia in the age group of 20–50 years of both sexes and the American Society of Anesthesiologists physical Status I and II were included in the study. Patients suffering from comorbidities predicted difficult intubation, prolonged laryngoscopy and intubation, and head-and-neck surgery were excluded from the study.
With anticipated mean and standard deviation (SD) of PR after 5 min in the lignocaine group of 90.27 and 14.83, respectively, and that in the esmolol group of 78.16 and 13.04, respectively, in the reference study, the minimum sample size per group is 27 patients with 90% power and 5% level of significance. It was computed using the following formula:
SD = Common SD. Sample size taken in each group was 30.
Patients in the esmolol and lignocaine groups on arrival to operation theater recorded basal parameters and premedicated with injection glycopyrrolate 0.01 mg/kg and injection midazolam 0.02 mg/kg 5 min before induction. After preoxygenation, Group I patients received esmolol 1.5 mg/kg and Group II patients received lignocaine 1.5 mg/kg IV 2 min before intubation and diluted with normal saline 10 ml. Patients were induced with injection thiopentone 5 mg/kg, followed by succinylcholine 1.5 mg/kg to facilitate intubation and ventilation. Laryngoscopy and endotracheal intubation were done with an appropriate-size endotracheal tube within 15–30 s in the first attempt and anesthesia was continued with O2, N2O halothane, and muscle relaxation.
The present study focused on events from the time of injection of study drugs up to 5 min after intubation. Adjuvants and analgesics were administered after the study period. At the following times on arrival to opertation theatre, during laryngoscopy and intubation, and after 1, 2, 3, 4, and 5 min of intubation, PR, SBP, and DBP readings were noted and MAP and RPP were calculated. Patients were monitored for conduction abnormalities, ST-segment changes with electrocardiography monitoring, hypotension, bradycardia, bronchospasm, and pain on injection. At the end of the surgery, the patients reversed with injection neostigmine 0.05 mg/kg and injection glycopyrrolate 0.01 mg/kg. Patients were followed up postoperatively for complications.
The collected data were analyzed using proper statistical tests such as Student's t-test, and data were represented by mean SD and graphs. Data were analyzed using statistical software SPSS version 17 (17.0 software, IBM Corp, Armonk NY, USA). P ≤ 0.05 was considered as statistically significant.
| Results|| |
In the study, the groups were collectively matched for their demographic data [Table 1]. There was a significant increase in mean PR in lignocaine group, which did not come back to baseline level even after 5 min. In the esmolol group, there was a significant attenuation of mean PR during and following intubation [Table 2] and [Figure 1]. Mean of MAP in lignocaine group showing a significant rise from baseline values, especially during and 1 and 2 min after laryngoscopy and endotracheal intubation. Mean of MAP in the esmolol group, there was a significant fall of the hypertensive response to laryngoscopy and endotracheal intubation [Table 3] and [Figure 2]. In this study, mean of RPP in lignocaine group, shows significant rise during and after intubation which did not reach the baseline value even after 5 min. There was a fall in mean RPP in esmolol group during intubation, which persisted even after 5 min [Table 4] and [Figure 3].
|Figure 2: Comparison of mean arterial pressure between esmolol and lignocaine|
Click here to view
|Figure 3: Comparison of rate pressure product between esmolol and lignocaine|
Click here to view
| Discussion|| |
The pressor response to the procedure of laryngoscopy and endotracheal intubation is a reflex response. Deep pressure on the base of the tongue is also responsible for such response. These stimuli activate suprasegmental and hypothalamic sympathetic centers to cause a peripheral sympathoadrenal response which releases catecholamines.
Esmolol short-acting cardioselective β-adrenergic antagonist permits rapid titration to a desired level of β-blockade on administration; hence, it a suitable agent for the perioperative period. At therapeutic doses, it does not have intrinsic sympathetic activity or membrane-stabilizing activity.,,,, In the literature, different doses of esmolol have been reviewed, but the selection of an effective dose of esmolol is essential to balance between desired effects and adverse effects.
Prajwal Patel et al. study received esmolol 1.5 mg/kg and labetalol 0.25 mg/kg 2 min before extubation and concluded that esmolol was more efficient than labetalol at extubation and immediately postextubation. Shailaja and Srikantu study in hypertensive patients received normal saline, esmolol 1.5 mg/kg, and esmolol 1.5 mg/kg with fentanyl 2 μg/kg during laryngoscopy and endotracheal intubation and concluded that esmolol 1.5 mg/kg is effective in attenuating hemodynamic response to laryngoscopy and intubation, but the combination of the drug causes hypotension following intubation. Talwar et al. study reported that esmolol (1.5 mg/kg) and esmolol with diltiazem were both effective in attenuating heart rate, SBP, DBP, and MAP after laryngoscopy and endotracheal intubation. Sharma et al. showed that esmolol 1.5 mg/kg and dexmedetomidine both suppress the hemodynamic response to intubation when compared to the control group. In accordance with the above studies, we preferred esmolol 1.5 mg/kg in our study and found significant results compared to lignocaine 1.5 mg/kg.
Helfman et al. reported that significant attenuation of heart rate, SBP in bolus doses of esmolol 200 mg. Singh et al. showed that esmolol 1.4 mg/kg was significantly more effective than lignocaine 1.5 mg/kg in minimizing the increase in MAP. We also found a significant reduction in MAP and PR in our study. Some study showed that patients with RPP greater than 12,000 developed ischemic electrocardiographic changes. Esmolol reduces RPP in van den Berg et al. study compared to lignocaine.
Lignocaine in attenuating the hemodynamic response during endotracheal intubation is due to direct cardiac depression and peripheral vasodilatation. It has antiarrhythmic and analgesic properties. In Marulasiddappa and Nethra study, the use of lignocaine 1.5 mg/kg is inadequate in comparison with clonidine to control heart rate and blood pressure in neurosurgical cases.
Oxorn et al., Sheppard et al., and Vucevic et al. reported that the only side effect of esmolol was phlebitis, which can be avoided by suitable dilution. There were no adverse effects seen in our study.
In our results, we found a difference in mean PR, MAP, and mean RPP between esmolol group and lignocaine group during laryngoscopy and endotracheal intubation as in similar study. However, we have not observed any complications in the study.
There were certain limitations to our study. We were unable to assess the plasma level of catecholamines during the study. We had taken only the changes in normotensive patients, not comorbid patients. Hence, further studies required to know the effective, accurate plasma concentration of the drug to prevent pressor response during laryngoscopy and intubation in risk patients.
| Conclusions|| |
Esmolol, an ultra-short-acting cardioselective beta-adrenergic antagonist in the bolus dose of 1.5 mg/kg intravenously, is effective in blunting the pressor response to laryngoscopy and endotracheal intubation when compared with intravenous lignocaine 1.5 mg/kg in general anesthesia without causing undue bradycardia and hypotension.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Tomori Z, Widdicombe JG. Muscular, bronchomotor and cardiovascular reflexes elicited by mechanical stimulation of the respiratory tract. J Physiol 1969;200:25-49.
Reid LC, Brace DE. Irritation of the respiratory tract and its reflex effect on the heart. Surg Gynecol Obstet 1940;70:157.
Shang NG. Pathophysiological effects of tracheal intubation. In Latto IP, Vaughan RS, editors. Difficulties in Tracheal Intubation. 2nd
ed. London: W. B. Saunders; 1997. p. 13-50.
Abou-Madi M, Keszler H, Yacoub O. A method for prevention of cardiovascular reactions to laryngoscopy and intubation. Can Anaesth Soc J 1975;22:316-29.
Derbyshire DR, Smith G, Achola KJ. Effect of topical lignocaine on the sympathoadrenal responses to tracheal intubation. Br J Anaesth 1987;59:300-4.
Miller CD, Warren SJ. IV lignocaine fails to attenuate the cardiovascular response to laryngoscopy and tracheal intubation. Br J Anaesth 1990;65:216-9.
Menkhaus PG, Reves JG, Kissin I, Alvis JM, Govier AV, Samuelson PN, et al.
Cardiovascular effects of esmolol in anesthetized humans. Anesth Analg 1985;64:327-34.
Cucchiara RF, Benefiel DJ, Matteo RS, DeWood M, Albin MS. Evaluation of esmolol in controlling increases in heart rate and blood pressure during endotracheal intubation in patients undergoing carotid endarterectomy. Anesthesiology 1986;65:528-31.
Miller DR, Martineace J. Esmolol for control of haemodynamic responses during anesthetic induction. Can J Anaesth 1989;36:S165-6.
Sheppard S, Eagle CJ, Strunin L. A bolus dose of esmolol attenuates tachycardia and hypertension after tracheal intubation. Can J Anaesth 1990;37:202-5.
Miller DR, Martineau RJ, Wynands JE, Hill J. Bolus administration of esmolol for controlling the haemodynamic response to tracheal intubation: The Canadian Multicentre Trial. Can J Anaesth 1991;38:849-58.
Yu SK, Tait G, Karkouti K, Wijeysundera D, McCluskey S, Beattie WS. The safety of perioperative esmolol: A systematic review and meta-analysis of randomized controlled trials. Anesth Analg 2011;112:267-81.
Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators, Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, et al.
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2012;307:2295-304.
Blessberger H, Kammler J, Domanovits H, Schlager O, Wildner B, Azar D, et al.
Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev 2018;3:CD004476.
Parvez G, Ommid M, Gupta AK, Heena H, Hasiha AH. Attenuation of pressor response to laryngoscopy and tracheal intubation with intravenous diltiazem and esmolol intravenous in controlled hypertensive surgical patients. Rev Colomb Anesthesiol 2010;38:457-69.
Singh S, Laing EF, Owiredu WK, Singh A. Comparison of esmolol and lidocaine for attenuation of cardiovascular stress response to laryngoscopy and endotracheal intubation in a Ghanaian population. Anesth Essays Res 2013;7:83-8. [Full text]
Prajwal Patel HS, Shashank MR, Shivaramu BT. Attenuation of hemodynamic response to tracheal extubation: A comparative study between esmolol and labetalol. Anesth Essays Res 2018;12:180-5.
Shailaja S, Srikantu J. Comparison of effect of esmolol vs. esmolol and fentanyl on hemodynamic response to laryngoscopy and tracheal intubation in controlled hypertensive patients: A randomized controlled double blind study. Anaesth Pain Intensive Care 2013;17:267-73.
Talwar V, Ganeriwal V, Aggarwal S, Gupta A. Efficacy of combination of esmolol and diltiazem for attenuating hemodynamic response to laryngoscopy and intubation: A prospective randomized study. Anesth Essays Res 2018;12:674-9.
] [Full text]
Sharma S, Suthar OP, Tak ML, Thanvi A, Paliwal N, Karnawat R. Comparison of esmolol and dexmedetomidine for suppression of hemodynamic response to laryngoscopy and endotracheal intubation in adult patients undergoing elective general surgery: A prospective, randomized controlled double-blinded study. Anesth Essays Res 2018;12:262-6.
] [Full text]
Helfman SM, Gold MI, DeLisser EA, Herrington CA. Which drug prevents tachycardia and hypertension associated with tracheal intubation: Lidocaine, fentanyl, or esmolol? Anesth Analg 1991;72:482-6.
Singh H, Vichitvejpaisal P, Gaines GY, White PF. Comparative effects of lidocaine, esmolol, and nitroglycerin in modifying the hemodynamic response to laryngoscopy and intubation. J Clin Anesth 1995;7:5-8.
Barash PG, Kopriva CJ. The rate-pressure product in clinical anesthesia: Boon or bane? Anesth Analg 1980;59:229-31.
van den Berg AA, Savva D, Honjol NM. Attenuation of the haemodynamic responses to noxious stimuli in patients undergoing cataract surgery. A comparison of magnesium sulphate, esmolol, lignocaine, nitroglycerine and placebo given i.v. With induction of anaesthesia. Eur J Anaesthesiol 1997;14:134-47.
Marulasiddappa V, Nethra HN. A comparative study of clonidine and lignocaine for attenuating pressor responses to laryngoscopy and endotracheal intubation in neurosurgical cases. Anesth Essays Res 2017;11:401-5.
] [Full text]
Oxorn D, Knox JW, Hill J. Bolus doses of esmolol for the prevention of perioperative hypertension and tachycardia. Can J Anaesth 1990;37:206-9.
Vucevic M, Purdy GM, Bills FR. Esmolol hydrochloride for management of the cardiovascular stress responses to direct laryngoscopy and tracheal intubation. Br J Anaesth 1992;68:529-30.
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2], [Table 3], [Table 4]